Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 13 Apr 23 RW Registration withdrawal request
- 11 Apr 23 FWP Free writing prospectus
- 3 Apr 23 EFFECT Notice of effectiveness
- 27 Mar 23 F-1/A Registration statement (foreign) (amended)
- 23 Mar 23 FWP Free writing prospectus
- 22 Mar 23 F-1/A Registration statement (foreign) (amended)
- 13 Mar 23 F-1/A Registration statement (foreign) (amended)
- 9 Mar 23 FWP Free writing prospectus
- 8 Mar 23 FWP Free writing prospectus
- 7 Mar 23 F-1/A Registration statement (foreign) (amended)
-
1 Mar 23 F-1/A Registration statement (foreign) (amended)
- 28 Feb 23 F-1/A Registration statement (foreign) (amended)
- 16 Feb 23 F-1 Registration statement (foreign)
CYTO similar filings
- 10 Apr 24 Registration statement (foreign)
- 16 Jun 23 Registration statement (foreign)
- 1 Jun 23 Registration statement (foreign)
- 1 Mar 23 Registration statement (foreign) (amended)
- 16 Feb 23 Registration statement (foreign)
- 16 Dec 22 Registration statement (foreign)
- 8 Feb 22 Registration statement (foreign)
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement No. 333-269823 on Form F-1 of our report dated April 12, 2022, relating to the financial statements of Altamira Therapeutics Ltd. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
Deloitte AG
/s/ Roland Mueller | /s/ Adrian Kaeppeli |
Zurich, Switzerland
March 1, 2023